Allergy Related Articles

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the
development of novel anti-inflammatory drugs, today announced that it has
initiated a Phase II equivalent study of MRX-4, in a nasal aerosol
formulation, in 105 patients suffering from allergic rhinitis (AR). The
two-arm, randomized, multi-dose, double-blind, placebo-controlled study
includes Rhinocort(R) as the steroid comparator arm. The study is expected to
be completed by the end of Buy soma pills Q3 2008.
The study is designed to evaluate the safety, tolerability, and efficacy
of intranasal MRX-4 in AR patients outside of the local allergy season as
compared with both placebo and an intranasal steroid. An experimental
multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal
potential treatment for AR that has generated promising pre-clinical efficacy
data. In a Phase I equivalent trial completed in Israel earlier this year, it
was shown to be well tolerated with no clinical significant adverse effects.
"We are excited about the opportunity to evaluate the safety and efficacy
of MRX-4 in a multi-dose trial for treating allergic rhinitis," said Mark
Cohen, chairman of the board of Morria. "MRX-4 could provide unique,
non-steroidal, first-choice drug treatment for allergic rhinitis."
According to Dr. Yuval Cohen, Morria’s president, it is rare for a
first-in-man efficacy study in AR (phase II) to include a steroid comparator
arm. "Most companies prefer waiting until they have generated substantial
clinical efficacy data comparing their drug to a placebo before venturing to
compare it to a standard market treatment, such as a nasal corticosteroid.
Our decision to include the steroid comparator arm so early in our clinical
development is a combination of our confidence in MRX-4’s performance as well
as the creativity of our clinical team in streamlining and maximizing the
efficacy of our clinical development program. We believe that this will
substantially increase the value of this data."
About Allergic Rhinitis
Allergic rhinitis is a common condition that affects nearly 59 million
people in the United States (nearly 20 percent of the population) with a
market of close to US$4 billion. Allergic rhinitis is characterized by
inflammation of the nasal membranes accompanied by symptoms that may include
sneezing, nasal congestion, nasal itching and rhinorrhea.
About Morria Biopharmaceuticals Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on
the development of novel anti-inflammatory pharmaceuticals termed
multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs
uniquely combines two promising approaches to preventing and reversing
inflammation: first, they control the phospholipase A2 (PLA2) enzyme family,
a known, but previously elusive anti-inflammatory drug target. At the same
time, they also protect cells and tissues against inflammatory damage. Morria
is determined to become a pivotal player in the US$20 billion
anti-inflammatory drug market by developing and commercializing novel drugs
for acute pulmonary and gastro-intestinal inflammatory diseases.
Morria Biopharmaceuticals Plc
View drug information on Rhinocort Aqua Nasal Spray.
Buy cipro pills | generic zithromax online buy | generic viagra online buy